Poolbeg Pharma PLC - PDMR Notification

Poolbeg Pharma plc
PDMR Notification
Cathal is a director of Horizon Medical Technologies Limited ("Horizon"), an investment vehicle of which Raglan Road Capital Limited, a company 100% owned and controlled by
To date, 100% of Horizon's holdings in Poolbeg have been included as part of the reported ownership of
The Poolbeg shares held by Horizon will be distributed to the underlying shareholders in Horizon, with 162,775 Poolbeg shares being distributed to the 10.5% shareholders in Horizon, who are separate and independent from
Upon completion of this process, Cathal's total shareholding will be 41,056,982 ordinary shares, representing 5.82% of the issued share capital of the Company, and as a result of this transaction Cathal's beneficial shareholding has not changed and remains at 41,056,982 ordinary shares.
Enquiries
|
Poolbeg Pharma Plc
|
+44 (0) 207 183 1499 |
|
Cavendish Capital Markets Ltd (NOMAD & Joint Broker) Harriet Ward (ECM)
|
+44 (0) 207 220 0500 |
|
Shore Capital Stockbrokers Ltd (Joint Broker)
|
+44 (0) 207 408 4090 |
|
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist
|
+353 (0) 1 679 6363 |
|
Optimum Strategic Communications
|
+44 (0) 208 078 4357 |

About Poolbeg Pharma plc
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.
Stay updated: Website | Sign up for RNS alerts | Presentation | X | LinkedIn
Forward-Looking Statements
This announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a. |
Name of PDMR |
|
|
|
2 |
Reason for notification
|
||
|
a. |
Position/Status |
Executive Chair |
|
|
b. |
Initial notification/ Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a. |
Name |
Poolbeg Pharma plc |
|
|
b. |
LEI |
213800UZ8WJLWYHBFL52 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a. |
Description of the financial instrument, type of instrument
|
Ordinary shares of
ISIN GB00BKPG7Z60 |
|
|
b. |
Nature of the transaction |
PDMR Notification |
|
|
c. |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
162,775 |
10.5% |
||
|
d. |
Aggregated information
- Aggregated Volume
- Price |
As in 4c) above
|
|
|
e. |
Date of the transaction |
|
|
|
f. |
Place of the transaction |
London Stock Exchange, AIM Market (XLON)
|
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE